Don't spend too much on your repeated translations.

Cut costs with Vikler Media. Visit: media.vikler.net

Europe

View All
April 2, 2025 0

Novadip appoints new CFO

By Dino Mustafić

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the appointment of Soumya Chandramouli as Chief Financial Officer (CFO). Soumya Chandramouli has 25 years’ experience in...

USA

View All
February 14, 2025 Off

Moderna reports full-year revenues of $3.2 billion, down from $6.8 in 2023 as Covid-19 vax sales drops

By Dino Mustafić

Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending...

My Pharmaceutical

View All
December 11, 2024 Off

Women urged to put breast density knowledge at the top of their Christmas list

By Dino Mustafić

 Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...

October 18, 2024 Off

Brenntag celebrates the company’s 150th anniversary in Essen, Germany

By Author

Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...

October 18, 2024 Off

Over-65s to benefit from potentially life-changing new treatment options thanks to technology-powered clinical trials initiative from Cera

By Dino Mustafić

Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...




April 2, 2025 0

Novadip appoints new CFO

By Dino Mustafić

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the appointment of Soumya Chandramouli as Chief Financial Officer (CFO).

Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare sectors with revenues of circa €500M, where she led a team of 50+ staff across multiple entities in North America and EMEA. Soumya recently contributed to a €93M private equity backed fundraising of a spin-off in the life sciences sector in Belgium.

Soumya’s experience in a globally deployed organization will be vital in supporting Novadip as it aims to become a commercial company with NVD003, its first autologous product, in the US, EU and Japanese markets in 2027, to address rare pediatric indications including Congenital Pseudarthrosis of the Tibia (CPT).

Novadip is planning a €50M Series C funding round with the aim of conducting two phase 3 trials with NVD003 and a Phase 2b/3 trial with NVDX3. The first patient in the NVD003 Phase 3 study in CPT will be enrolled in Q2, 2025. With access to the FDA’s Priority Review Voucher (>$150M), NVD003 could generate significant revenues. From 2027 to 2029, the commercial deployment of NVD003 for CPT will be associated with an increase in its clinical indications. Novadip’s Phase 2b/3 trial with NVDX3, its allogenic cell-derived product, will target spine fusion and trauma indications. The company is also developing its cell-free platform for the treatment of bone tumors and skin healing.